[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640754":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":48,"collaborators":19,"id":50,"slug":19,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":19,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Children's Hospital Medical Center, Cincinnati","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Quercetin","EXPERIMENTAL","Quercetin dose (based on patient weight and as a percentage of adult dose - as noted in Table 2) will be given orally on a twice a day schedule starting with weight adjusted maximum total daily dose of 4000 mg\u002Fday (and administered in divided doses bid). For patients who weigh 70 kg or more, the starting dose will be automatically assigned at the maximum dose of 4000 mg\u002Fday.",[13],"Drug: Quercetin",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Quercetin (3, 30, 40, 5, 7-pentahydroxyflavone) is a naturally occurring antioxidant that belongs to a group of polyphenolic compounds known as flavonoids. Quercetin is routinely available as an over-the-counter product due to it being a nutritional supplement. However, for the purpose of the study, it will be purchased in the powder form from PCCA (supplied as 96% quercetin dihydrate) and stored and distributed by the investigational pharmacy at CCHMC using standard operational procedures.\n\nQuercetin is administered as an oral medication, supplied in powder form. Quercetin will be stored at room temperature. The product will be dispensed for home administration. Each packet will be labeled in accordance with applicable regulatory requirements. Patients or parents will be instructed to mix it with a small amount of yogurt or other preferred food for ingestion.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Parinda Mehta, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Sara Loveless","CONTACT","513-803-7656","sara.loveless@cchmc.org",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Cincinnati Children's Hospital Medical Center","RECRUITING","Cincinnati","Ohio","45229","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-84.51439,39.12711,{"lat":43,"lon":42},[46,47],{"name":26,"role":27,"phone":19,"phoneExt":19,"email":29},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":49,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100640754",false,"NCT07628972","Quercetin Dyskeratosis Congenita (DC)\u002FTelomere Biology Disorders (TBD)","Pilot Study of Quercetin Patients With Dyskeratosis Congenita\u002FTelomere Biology Disorders","Inclusion Criteria:\n\n1. Diagnosis of DC\u002FTBD deficiency as defined by at least one of the following:\n\n   * Age adjusted mean-telomere length of \\\u003C1 percentile in all tested peripheral blood cells such as granulocytes, lymphocytes, B-cells, naïve T-cells, memory T-cells, and NK cells\n   * A pathogenic or likely pathogenic mutation in DKC1, TERC, TERT, NOP10, NHP2, TINF2, CTC1, PARN, RTEL1, ACD, NAF1, ZCCHC8, or WRAP53\n2. Patients ≥ 2.0 years of age\\*\n\n   * The first three enrolled patients must be ≥ 10.0 years of age\n3. Able to take medication orally\n\nExclusion Criteria:\n\n1. Renal failure requiring dialysis\n2. Total bilirubin \\>3 mg\u002Fdl and\u002For SGPT \\>300 at time of enrollment, unless elevation thought to be related to DC\u002FTBD\n3. Patients who have received quercetin or any over-the-counter antioxidant supplementation within last 1 month\n4. Patients currently taking androgen therapy\n5. Patients receiving digoxin therapy, who are unable to discontinue treatment due to medical reasons\n6. Patients receiving fluoroquinolone therapy, who are unable to discontinue treatment due to medical reasons\n7. Patients who are pregnant or breastfeeding or are at risk of pregnancy and are unable to use acceptable methods of birth control during the length of the study\n8. Patients with morphologic or cytogenetic evidence of myelodysplasia or leukemia.\n9. Patients needing to start or actively receiving radiation therapy, chemotherapy or immunotherapy for treatment of SCC or other cancers.\n10. Patients with unstable disease status or other medical issues requiring hospitalization or rapid escalation of medical care\n11. Participating in another therapeutic study for DC\u002FTBD\n12. Patients who are in the early post-stem cell transplant period (i.e. first 6 months post-transplant)","ALL","2 Years",{"count":59,"type":60},12,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","The purpose of this study is to see if a vitamin-like substance called quercetin is safe for people who have a rare condition called Dyskeratosis congenita (DC) or telomere biology disorders (TBD).",[66,67],"Dyskeratosis Congenita","Telomere Disease","2026-06-01",{"date":70,"type":71},"2026-06-05","ACTUAL",{"date":73,"type":71},"2026-05-29",{"date":75,"type":60},"2028-09",{"name":5,"class":6},1]